Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. The findings do not support CBD as an effective standalone treatment for fibromyalgia pain based on current evidence. Clinicians should counsel patients accordingly and avoid recommending CBD for fibromyalgia outside of a structured clinical context until stronger evidence emerges.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomised controlled trial provides the first rigorous clinical evidence evaluating CBD’s efficacy for fibromyalgia pain, addressing a significant evidence gap given widespread off-label use of this agent in this patient population. The findings will inform clinical decision-making regarding CBD as a potential pharmacological option for fibromyalgia management and help establish whether observed benefits reflect true therapeutic effect or placebo response. Given fibromyalgia’s limited treatment options and the opioid crisis, demonstrating CBD’s efficacy or lack thereof has important implications for treatment algorithms and patient safety considerations.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This double-blind, placebo-controlled trial provides a rigorous assessment of CBD for fibromyalgia pain, addressing a gap in the evidence base for a condition where patients often seek cannabis-based treatments. While the study design is methodologically sound, the single-center recruitment from a specialized Danish clinic may limit generalizability to broader fibromyalgia populations with varying disease severity, comorbidities, and concurrent medications that could influence CBD efficacy or safety. The complexity of fibromyalgia itself, involving central sensitization and multiple neurotransmitter systems, suggests that CBD’s mechanism of action in this condition remains incompletely understood and may differ significantly from its established effects in other indications. Clinically, this evidence should inform more nuanced counseling conversations with fibromyalgia patients considering CBD, emphasizing that while the compound warrants investigation, we should continue individualizing treatment decisions rather than assuming efficacy across all patients, and remain alert to potential drug-drug interactions given the polypharmacy common in